Tranexamic acid to reduce bruising after facial filler injections
Does TXA Reduce Bruising After Hyaluronic Acid Filler Injection? A Prospective Half Face Study
This will test whether adding tranexamic acid to hyaluronic acid injections reduces bruising, swelling, and tenderness in adults getting facial fillers.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 89 Years |
| Sex | All |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Trial ID | NCT06665594 on ClinicalTrials.gov |
What this trial studies
This Phase 2 interventional trial compares standard hyaluronic acid (HA) facial filler injections to HA plus tranexamic acid (TXA) using a half-face design so each participant serves as their own control. One side of the face receives HA alone and the other side receives HA+TXA, with outcomes measured by participant surveys, physician assessments, and medical record review. The trial tracks bruising, swelling, pain, and overall satisfaction after injections and monitors safety events related to TXA. Results will inform whether co-administration of TXA is safe and reduces common post-filler side effects.
Who should consider this trial
Good fit: Adults aged 18–89 seeking bilateral facial hyaluronic acid injections who can consent and speak English and who do not have clotting disorders, recent thrombotic events, active anticoagulation or aspirin use, severe renal failure, diabetes, seizure disorder, current tobacco use, pregnancy, breastfeeding, or known TXA allergy are ideal candidates.
Not a fit: People who are pregnant or breastfeeding, on therapeutic anticoagulation or aspirin, have a history of thrombosis, severe renal failure, diabetes, seizures, current tobacco smokers, have color vision defects, or who are getting unilateral injections would be excluded and would not receive benefit from this protocol.
Why it matters
Potential benefit: If successful, adding TXA could lower bruising, swelling, and pain after hyaluronic acid filler injections, speeding recovery and improving patient satisfaction.
How similar studies have performed: TXA has shown benefit reducing bleeding and bruising in some surgical and dermatologic settings, but co-injecting TXA with hyaluronic acid for filler-related bruising is relatively novel and not well-studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age equal to or greater than 18 but less than or equal to 89 years. * Participants interested in facial filler (HA) injection. * English speaking. Exclusion Criteria: * Minors or under the age of 18 * Participant over the age of 89 * Pregnant or breast-feeding women * Individuals unable to give consent due to another condition such as impaired decision-making capacity. * Individuals with a history of a thrombotic event (DVT, PE, stroke, MI) or genetic disorder that increases risk of thrombosis * Participants undergoing unilateral facial filler (HA) injection * Participants with history of hypersensitivity to TXA or any of the other ingredients * Participants that are on current therapeutic anticoagulation therapy and aspirin use * Participants with stage 2 or greater renal failure * Participants on hemodialysis or peritoneal dialysis * History of diabetes or seizures * Current tobacco smokers * Acquired defective color vision
Where this trial is running
Madison, Wisconsin
- University of Wisconsin - Madison — Madison, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Daniel Cho, MD, PhD — University of Wisconsin, Madison
- Study coordinator: Armin Edalatpour, MD
- Email: edalatpour@wisc.edu
- Phone: 608-263-7502
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.